JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD

Reference Data

ISIN LU2050612402
Valor Number
Bloomberg Global ID
Fund Name JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD
Fund Provider J.P. Morgan Bank Luxembourg S.A. 6, route de Trèves
L-2633, Senningerberg
Grand Duchy of Luxembourg
Fund Provider J.P. Morgan Bank Luxembourg S.A.
Representative in Switzerland JPMorgan Asset Management (Switzerland) LLC
Genève
Phone: +41 22 744 11 11
Distributor(s) JP Morgan Asset Management (Europe) Sàrl
Senningerberg
Phone: +352 34 10 1
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally.
Peculiarities

Fund Prices

Current Price * 113.54 USD 20.01.2026
Previous Price * 115.86 USD 16.01.2026
52 Week High * 117.91 USD 07.01.2026
52 Week Low * 72.17 USD 09.04.2025
NAV * 113.54 USD 20.01.2026
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 412,615,114
Unit/Share Assets *** 110,654,847
Trading Information SIX

Performance

YTD Performance +1.30% 31.12.2025
20.01.2026
YTD Performance (in CHF) +1.88% 31.12.2025
20.01.2026
1 month +0.02% 22.12.2025
20.01.2026
3 months +6.45% 20.10.2025
20.01.2026
6 months +29.42% 21.07.2025
20.01.2026
1 year +27.02% 21.01.2025
20.01.2026
2 years +12.63% 22.01.2024
20.01.2026
3 years +2.89% 20.01.2023
20.01.2026
5 years -40.10% 20.01.2021
20.01.2026

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

PTC Therapeutics Inc 3.52%
Ionis Pharmaceuticals Inc 3.47%
Krystal Biotech Inc 3.23%
Sumitomo Pharma Co Ltd 3.22%
Astellas Pharma Inc 3.10%
Amgen Inc 3.07%
Novartis AG Registered Shares 3.07%
Gilead Sciences Inc 3.05%
Alnylam Pharmaceuticals Inc 2.95%
Bio-Techne Corp 2.77%
Last data update 30.11.2025

Cost / Risk

TER *** 0.95%
TER date *** 30.06.2025
Performance Fee ***
PTR
Max. Management Fee *** 0.72%
Ongoing Charges *** 0.96%
SRRI ***
SRRI date *** 31.12.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)